City of Mason pilots forward-thinking approach to managing cardiovascular disease and advancing heart health literacy
MASON, Ohio – December 20, 2024 – The City of Mason and Genetesis, Inc. are again forging new ground in the fight against heart disease, which has remained the leading cause of death in the U.S. for over a century now. The City of Mason expanded its partnership with cardiac imaging startup Genetesis, which launched its newCardioFlux Membership program on Dec. 11, by becoming its first commercial client. With a strong track record, Mason’s proprietary living lab initiative will continue to leverage its diverse demographic population and scientific business community to scale young HealthTech companies while improving personal health outcomes for its own residents.
Earlier this month, Genetesis launched the CardioFlux Membership program to make its revolutionary magnetocardiography technology, known as CardioFlux MCG, directly accessible to the general public. Through its first CardioFlux Imaging Institute, now open in the City of Mason, participating members can schedule their own fully noninvasive MCG scans to track changes in their myocardial fitness (defined as the health of their heart muscle) over time by receiving personalized CardioFlux Scores. The current version of this Score analyzes 14 unique biomarkers that quantify the heart muscle’s electrical activity and compares those results to a benchmark of healthy, symptom-free individuals. The Score is highly sensitive to changes in cardiac muscle that may arise due to lifestyle changes, new medications, significant health events and aging.
“We’ve believed for along time that the City of Mason’s commitment to HealthTech companies like ours is more than a partnership. It redefines how we move business innovation forward and has allowed us to advance ideas and technology faster,” said Peeyush Shrivastava, Co-Founder and CEO of Genetesis. “Mason leadership has always challenged us to think differently about how we can pilot programs together that not only advance the current standard of care but also have the potential to improve heart health outcomes for the city’s population as a whole. My team is beyond excited for how we can improve heart health right herein our backyard.”
“The City of Mason’s Mason Living Lab was established to accelerate the advancement of science and technology across the Mason BioHub and the broader community,” said MicheleBlair, Economic Development Director at City of Mason. “Over the past seven years, our collaboration with Genetesis has reshaped the possibilities of this initiative. The Myocardial Fitness Membership pilot – our fourth project together – furthers this new technology in cardiac science and creates a powerful ‘win-win’ model: driving faster exposure while delivering cutting-edge science directly to the community. We are very excited to be the first commercial adopter.”
“Our company’s mission is to eliminate heart disease,” said Vineet Erasala, Co-Founder and COO at Genetesis. “Our belief is that empowering people by letting them know how healthy – or unhealthy – their heart truly is long before they develop symptoms indicative of disease is an essential step in realizing that vision.”
The City of Mason has deep experience adopting and bringing awareness to transformative technologies by innovators in the Mason BioHub. This work includes companies such as Myriad Genetics, AtriCure, Clarigent Health, Mira Precision Health, Include Health, and Genetesis. The City’s LivingLab initiatives have contributed to early-stage scientific explorations while helping companies scale through commercial launches and successful exits.
“We have moved beyond the traditional public-private partnership (P3) model and are now regularly leaning into our ‘City as a Lab’ concept, which brings city residents and employees in almost as a fourth partner in advancing new technology,” said Jessica Johnson, Corporate Strategy at City of Mason. “This ‘P4’ approach makes scaling life science companies a much more tangible proposition as we watch young companies grow.”
“As simple a concept as early monitoring is, CardioFlux Membership is revolutionary in how we can make innovative technology like MCG directly available to the public. What our team has built and delivered here in Mason is a template for how we plan to scale our mission across the nation,” said Shrivastava.
About the City of Mason, Ohio
As the largest city in Warren County and part of the Greater Cincinnati region in southwest Ohio, Mason is an established hub for biohealth and biotech life science companies, with focus areas in cardiology, mental health and precision medicine. With over $600 million in new investment and more than 1,200 jobs announced in 2024 primarily in life sciences, the city continues to build this foundation, as well as its advanced manufacturing, aerospace and automation sectors. Fortune Well ranks Mason at No. 5 on its list of the Top 50 best places to live for families in the U.S. With national recognition around its low cost of living and award-winning schools, Mason continues to attract top talent and partnerships, which contribute to its dynamic culture and sense of place.
For more information about the City of Mason, visit www.whymason.com or www.imaginemason.org.
Contact
Mimi Rasor
Mimi@gorasor.com
(513) 910-8385
About Genetesis
In pursuit of a world without heart disease, Genetesis, Inc.has translated over 60 years of magnetocardiography research into CardioFlux MCG, a 90-second cardiac imaging modality administered without the need for ionizing radiation, pharmaceuticals, or exercise-induced stress. CardioFlux MCG has already been 510(k) cleared by the FDA and is currently being further evaluated for its specific utility in both diagnostic and preventive cardiac applications.
Headquartered just north of Cincinnati, Ohio, Genetesis has been working to understand how MCG technology can unlock a world of superior cardiac insights since 2013.
For more information about Genetesis, visit https://www.genetesis.com.
For more information about accessing CardioFlux MCG as a potential user, visit https://www.cardioflux.com.
Contact
Ryan Yoo
Chief of Staff
ryan.yoo@genetesis.com
(949) 742-0562